Adverum Biotechnologies Reports Aflibercept Protein Level Data From LUNA Phase 2 Trial; Says Ixo-vec Has Been Well Tolerated With Favorable Preliminary Safety Profile
Portfolio Pulse from Benzinga Newsdesk
Adverum Biotechnologies has reported Aflibercept protein level data from its LUNA Phase 2 trial. The company states that Ixo-vec has been well tolerated with a favorable preliminary safety profile.
September 26, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adverum Biotechnologies' LUNA Phase 2 trial data shows Ixo-vec has a favorable preliminary safety profile, which could positively impact the company's stock.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. In this case, Adverum Biotechnologies' announcement of favorable preliminary safety profile for Ixo-vec from its LUNA Phase 2 trial could lead to increased investor interest and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100